ReviewJournal of clinical microbiology2018
Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests.
Review in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Point-of-Care Nucleic Acid Amplification Tests for Respiratory Syncytial Virus Detection in Children and Adults: A Systematic Literature Review.Infectious diseases and therapy · 2026Pooled it
- Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2021Guideline
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Awareness of respiratory syncytial virus and other respiratory disease vaccines among healthcare professionals and their patients in Italy: Insights from a literature review and a web-based survey.Human vaccines & immunotherapeutics · 2025Review
- Comparison of Sofia 2 Respiratory Syncytial Virus Fluorescent Immunoassay to Real-Time Polymerase Chain Reaction Assay in Children Under Two Years Old Hospitalized With Acute Respiratory Illness in Amman, Jordan: A Cross-Sectional Study.Health science reports · 2025Article
- Advancing Laboratory Diagnostics for Future Pandemics: Challenges and Innovations.Pathogens (Basel, Switzerland) · 2025Review
- A multicenter study to assess the performance of the point-of-care RT-PCR Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system in comparison with centralized assays across healthcare facilities in the United States.Journal of clinical microbiology · 2025Article
- Rapid diagnosis of acute pediatric respiratory infections with Point-of-Care and multiplex molecular testing.Infection · 2025Review
- Human metapneumovirus (hMPV) in 2025: emerging trends and insights from community and hospital-based respiratory panel analyses-a comprehensive review.Virology journal · 2025Review
- Epidemiology of respiratory viruses according to age group, 2023-24 winter season, Kyoto, Japan.Scientific reports · 2025Article
- Development of a multiplex real-time RT-PCR assay for simultaneous detection of 18 respiratory viruses.Frontiers in cellular and infection microbiology · 2025Article
- Next generation sequencing as a panacea for antibiotic susceptibility testing: yea or nay?Frontiers in public health · 2025Article
- Diagnostic Accuracy of the LabTurbo QuadAIO Common Flu Assay for Detecting Influenza A Virus, Influenza B Virus, RSV, and SARS-CoV-2.Diagnostics (Basel, Switzerland) · 2024Article
- Seasonal Influenza in Children With Cancer.Cureus · 2024Review
- Guidelines for Antibiotics Prescription in Critically Ill Patients.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- At-home testing for respiratory viruses: a minireview of the current landscape.Journal of clinical microbiology · 2024Review
- Accurate detection of influenza A virus by use of a novel cross-priming isothermal amplification-based point-of-care assay.Microbiology spectrum · 2024Article
- Review
- Article
- Improvement of Sensitivity and Speed of Virus Sensing Technologies Using nm- and μm-Scale Components.Sensors (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
An accurate laboratory diagnosis of influenza, respiratory syncytial virus (RSV), and other respiratory viruses can help to guide patient management, antiviral therapy, infection prevention strategies, and epidemiologic monitoring. Influenza has been the primary driver of rapid laboratory testing due to its morbidity and mortality across all ages, the availability of antiviral therapy, which must be given early to have an effect, and the constant threat of new pandemic strains. Over the past 30 years, there has been an evolution in viral diagnostic testing, from viral culture to rapid antigen detection, and more recently, to highly sensitive nucleic acid amplification tests (NAAT), as well as a trend to testing at the point of care (POC). Simple rapid antigen immunoassays have long been the mainstay for POC testing for influenza A and B viruses and respiratory syncytial virus (RSV) but have been faulted for low sensitivity. In 2015, the first POC NAAT for the detection of influenza was approved by the Food and Drug Administration (FDA), ushering in a new era. In 2017, the FDA reclassified rapid influenza diagnostic tests (RIDTs) from class I to class II devices with new minimum performance standards and a requirement for annual reactivity testing. Consequently, many previously available RIDTs can no longer be purchased in the United States. In this review, recent developments in Clinical Laboratory Improvement Amendments of 1988 (CLIA)-waived testing for respiratory virus infections will be presented, with the focus on currently available FDA-cleared rapid antigen and molecular tests primarily for influenza A and B viruses and RSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.